JnJ presents about imtelstat as part of their oncology program (17 May 2017)

[Fishermangents]

On May 17 Peter Lebovitz (Global Therapeutic Area Head, Oncology) of JnJ presented about their oncology program. Imetelstat is mentioned on slide 5, 14, 16, 34, 37 and 55.

link to the oncology presentation: http://files.shareholder.com/downloads/ ... Slides.pdf
link to webcast and all presentations: http://www.investor.jnj.com/events.cfm

In their press release they mentioned imetelstat in their list of 10 future blockbuster drugs. From the press release:

Additional late-stage blockbuster products projected to file for regulatory approvals between 2017 and 2021, include:
- apalutamide (ARN-509) for pre-metastatic prostate cancer;
- esketamine for treatment-resistant depression;
- talacotuzumab (CSL362) for acute myeloid leukemia;
- erdafitinib (FGFR Inhibitor) for solid tumors;
- niraparib for prostate cancer;
- imetelstat for myelofibrosis;
- pimodivir (JNJ-3872) for influenza A;
- lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection; and,
- JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for major depressive disorder.

link to the press release: http://www.prnewswire.com/news-releases ... 58974.html